
Biogen Pharmachem Industries Falls to 52-Week Low of Rs.0.72
2025-12-05 15:47:04Biogen Pharmachem Industries has reached a new 52-week low, with its share price touching Rs.0.72 today. This marks a significant decline from its 52-week high of Rs.1.29, reflecting ongoing pressures within the company amid a broader market environment where the Sensex is trading near its yearly peak.
Read More
Biogen Pharmachem Industries Stock Falls to 52-Week Low of Rs.0.73
2025-12-03 15:36:40Biogen Pharmachem Industries has reached a new 52-week low, with its share price touching Rs.0.73 today. This marks a significant decline over the past year, reflecting ongoing pressures within the company and the broader market environment.
Read More
Biogen Pharmachem Industries Falls to 52-Week Low of Rs.0.74
2025-12-01 11:08:47Biogen Pharmachem Industries has reached a new 52-week low of Rs.0.74, marking a significant decline in its stock price amid broader market gains. The stock has underperformed its sector and continues to trade below all key moving averages, reflecting ongoing pressures within the company’s financial performance.
Read MoreWhy is Biogen Pharma falling/rising?
2025-11-19 22:32:25As of 19-Nov, Biogen Pharmachem Industries Ltd is experiencing a decline in its stock price, currently at Rs 0.78, which reflects a decrease of Rs 0.01 or 1.27%. The stock has underperformed significantly, with a 1-week return of -3.70% and a 1-month return of -6.02%. Additionally, it is trading lower than all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. The stock is also close to its 52-week low, just 3.85% above Rs 0.75. Furthermore, there has been a notable drop in investor participation, with delivery volume falling by 13.13% compared to the 5-day average, indicating reduced interest in trading the stock. In the broader market context, Biogen Pharma's performance contrasts sharply with the Sensex, which has gained 0.85% over the past week and 1.47% over the past month. Year-to-date, Biogen's stock has plummeted by 33.90%, while the Sensex has risen by 9.02%. ...
Read More
Biogen Pharma Faces Financial Challenges Amidst Mixed Profitability Trends
2025-11-10 08:00:12Biogen Pharmachem Industries, a microcap in the NBFC sector, reported a flat performance for the quarter ending September 2025, with a decline in financial metrics. Despite a higher profit after tax of Rs 0.85 crore over six months, the company faces significant challenges, including low quarterly profit figures and a substantial stock decline.
Read MoreHow has been the historical performance of Biogen Pharma?
2025-11-09 22:39:21Answer: The historical performance of Biogen Pharma shows significant fluctuations in its financial metrics over the years. Breakdown: Biogen Pharma's net sales have remained at zero from March 2023 to March 2025, following a modest increase to 2.47 crore in March 2022 from 1.62 crore in March 2021. Other operating income peaked at 2.38 crore in March 2024 but dropped to zero in March 2025. Total operating income followed a similar trend, reaching 2.16 crore in March 2022 before declining to zero by March 2025. The company faced a total expenditure of 1.13 crore in March 2025, a significant increase from 0.45 crore in March 2024, while operating profit (PBDIT) turned negative at -0.29 crore in March 2025, contrasting with a profit of 1.93 crore in March 2024. Profit before tax also fell to -0.29 crore in March 2025 from 1.93 crore in the previous year. The company's reserves have been negative, reaching -9...
Read MoreWhen is the next results date for Biogen Pharma?
2025-10-31 23:16:31Biogen Pharma is scheduled to declare its results on November 7, 2025....
Read MoreWhy is Biogen Pharma falling/rising?
2025-10-15 22:09:31As of 15-Oct, Biogen Pharmachem Industries Ltd is experiencing a decline in its stock price, currently at 0.83, which reflects a decrease of 0.01 or 1.19%. The stock has underperformed its sector by 2.96% today and has been on a consecutive downward trend for the last three days, resulting in a total decline of 4.6% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The stock has also shown significant underperformance over various time frames, with a year-to-date decline of 29.66% compared to a 5.72% increase in the benchmark index, Sensex. Unfortunately, there is no information available regarding positive or negative factors that could influence the stock's recent movement. Broader Market Context: In the short term, Biogen Pharma's performance has been notably weaker than the benchmark, as it has decli...
Read MoreWhy is Biogen Pharma falling/rising?
2025-10-07 22:17:11As of 07-Oct, Biogen Pharmachem Industries Ltd is experiencing a price increase, with its current price at 0.88, reflecting a change of 0.04 or 4.76% upwards. The stock has shown a performance today that outperformed its sector by 6.24%. In terms of returns, over the past week, the stock has increased by 6.02, while it has seen a decline of 1.12% over the past month and a significant drop of 25.42% year-to-date. Despite these longer-term declines, the recent rise in delivery volume, which increased by 4.21% against the 5-day average, indicates a growing interest among investors, contributing positively to the stock's recent upward movement. Unfortunately, there is no specific information available regarding positive or negative factors impacting the stock. Broader market context shows that while Biogen's short-term performance has been strong, with a 6.02% increase over the past week, it has still lagged b...
Read MoreBoard Meeting Outcome for Outcome Of The Board Meeting Of The Board Held On 7Th November 2025.
07-Nov-2025 | Source : BSEPursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held on today i.e. Friday 07th November 2025 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter and half year ended as on 30th September 2025. The board meeting commented at 03:30 PM and concluded at 04:00 PM Please take the above intimation in your records. Thanking You.
Regulations 30 33 And Other Applicable Provisions Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
07-Nov-2025 | Source : BSEPFA
Regulations 30 33 And Other Applicable Provisions Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
07-Nov-2025 | Source : BSEPFA
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






